In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Clinical trials have shown the mRNA vaccines for COVID-19 are safe and effective, especially at preventing severe illness, ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Note that some links may require registration or subscription. Experiments showed that the recommended 6 feet of social ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...